Menopausal Hot Flashes Global Market Report 2023 – By Type (Hormonal Treatment, Non-hormonal Treatment, Alternative Treatment), By Pipeline Analysis (Phase III Drugs, Phase I and II Drugs), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies), By Application (51-55 Year Old Woman, 46-50 Year Old Woman, 40-45 Year Old Woman) – Market Size, Trends, And Global Forecast 2023-2032

Women's health is the area of medicine that focuses on the identification and management of ailments and illnesses that have an impact on a woman's physical and psychological health. The main types of products for women's health include devices, drugs, and pharmaceutical pipelines. Women's health devices are the devices that are used to cure medical diseases of women. Women aged 50 years and older and others undergo hormonal treatment, non-hormonal treatment, and surgeries for various applications, including postmenopausal osteoporosis, hormonal infertility, endometriosis, uterine fibroids, contraceptives, menopause, and polycystic ovary syndrome (PCOS), through various distribution channels such as hospitals, retail stores, and online pharmacies. The global women's health market is segmented - 1) By Product Type: Devices, Drugs, Pharmaceutical Pipeline 2) By Age: 50 Years & Above; Other Ages 3) By Treatment Type: Hormonal Treatment, Non-Hormonal Treatment, and Surgery 4) By Application: Postmenopausal Osteoporosis, Hormonal Infertility, Endometriosis & Uterine Fibroids, Contraceptives, Menopause, Polycystic Ovary Syndrome (PCOS) 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global women's health market size is expected to grow from $39.43 billion in 2022 to $41.40 billion in 2023 at a compound annual growth rate (CAGR) of 5.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global women's health is expected to grow to $49.86 billion in 2027 at a CAGR of 4.8%. The rising prevalence of women-centric diseases is expected to propel the growth of the women's health market going forward. The women-centric diseases such as anemia, osteoporosis, breast cancer, menopause, and others are highly occurring due to various risk factors such as family history, increasing age, early onset of periods or menopause after 55 years, obesity, and others. This rising prevalence of women-centric diseases drives demand for women's health products and services that are required to treat these diseases and ensure the health and wellness of women. For instance, the World Health Organization (WHO), a specialized institution based in Switzerland responsible for global public health, estimates that in 2020, 2.3 million women received a breast cancer diagnosis, and there will be 685,000 fatalities worldwide. Breast cancer was the world’s most prevalent cancer, as there were 7.8 million women diagnosed with it in the past 5 years. Therefore, the rising prevalence of women-centric diseases is driving the growth of the women's health market. Major players in the women's health market are AbbVie Inc., Bayer AG, Merck & Co. Inc., Pfizer Inc., Agile Therapeutics, Amgen Inc., Apothecus Pharmaceutical Corporation, Blairex Laboratories Inc., Novartis AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Lupin Pharmaceuticals Inc., Johnson & Johnson Services Inc., Allergan Plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Siemens AG, and Hologic Inc. Developments in women's health are a key trend in the women's health market. Major companies operating in the women's health market are developing new products to strengthen their position. For instance, in November 2021, FemTec Health, a US-based startup that focuses on women's health and beauty using technology and data to personalize care, developed a data analytics platform and infrastructure called BiomeAI to customize care by using genetic, consumer, microbiome, and biometric data. The BiomeAI engine uses deep machine learning and AI to translate this data into the delivery of holistic healthcare personalized for every woman. In May 2021, Partners Group, a Switzerland-based global private equity firm, acquired Axia Women's Health for an undisclosed amount. With this acquisition, Partners Group added one more growing portfolio to its North American healthcare businesses. Axia Women's Health is a US-based women's healthcare services firm operating in the women's health market. North America was the largest region in the women's health market in 2022. Asia-Pacific is expected to be the fastest-growing region in the women's health market report during the forecast period. The regions covered in the women's health industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the women's health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The women's health market consists of revenues earned by entities by providing hormone therapy, birth control treatment, and other related services. The market value includes the value of related goods sold by the service provider or included within the service offering. The women's health market also includes sales of contraceptive devices and pharmaceuticals, densitometry, breast implants, obstetrics or gynaecology biopsy, imaging devices, and drugs such as Xgeva, Evista, Mirena, Zometa, Reclast, and Class, among others, that are used in providing women's health services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The women’s health market research report is one of a series of new reports from The Business Research Company that provides women’s health market statistics, including women’s health industry global market size, regional shares, competitors with a women’s health market share, detailed women’s health market segments, market trends and opportunities, and any further data you may need to thrive in the women’s health industry. This women’s health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hot food processing is used in the preservation of food by destroying microorganisms and reducing moisture in food. Hot food processing equipment refers to food processing equipment that can alter the physical, chemical, biochemical, and biological properties of the food, improving its overall quality, including ovens, blanchers, dryers, and heat exchangers. The hot food processing includes revenue earned by entities by providing of blanching, pasterurization, sterilization, infrared heater.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The main types of hot food processing equipment are baking equipment, evaporation equipment, pasteurisation equipment, dehydration equipment, roasting and grilling equipment, frying equipment, sterilisation equipment, blanching equipment, and others. Baking equipment refers to tools, utensils, and appliances used in cooking grain products like bread and pastries. The different modes of operation include automatic, semi-automatic, and manual, and are used by end-users such as food processing industries, food service industries, and households. The global hot food processing equipment market is segmented - 1) By Type: Baking Equipment, Evaporation Equipment, Pasteurization Equipment, Dehydration Equipment, Roasting and Grilling Equipment, Frying Equipment, Sterilization Equipment, Blanching Equipment, Other Types 2) By Mode of Operation: Automatic, Semi-Automatic, Manual 3) By End-User: Food Processing Industries, Food Service Industry, Household The global hot food processing equipment market size grew from $21.73 billion in 2022 to $23.4 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of the hot food processing equipment market size is expected to grow to $30.92 billion in 2027 at a CAGR of 7.2%. Rising demand for fast food and packaged food is expected to propel the growth of the hot food processing equipment market going forward. Fast-food and packaged foods are types of foods that save time in food acquisition, preparation, and preparation and are ready-to-eat foods from grocery stores. Hot food processing equipment is used to handle, cook, prepare, store, and package food and food products. For instance, according to the Press Information Bureau, a nodal agency of the Government of India, India exported more than $2.14 billion worth of final food products in 2020–21. The export of products under the ready-to-eat (RTE), ready-to-cook (RTC) and ready-to-serve (RTS) categories rose by more than 23% to $1011 million from April to October (2021-22), compared to $800 million reported in April to October (2020-21). Therefore, the rise in demand for fast food and packaged food is driving the hot food processing equipment market. Major companies operating in the the hot food processing equipment market are GEA Group AG, Buhler AG, The Middleby Corporation, JBT Corporation, SPX Flow, Tetra Laval International S.A, Alfa Laval AB, TNA Australia Pty Limited, BMA Braunschweigische Maschinenbauanstalt AG, Bongard, Marlen International Inc., Paul Mueller Company, NICHIMO Co., Ltd., Bucher Industries AG, Equipamientos Carnicos S.L., Clextra. Technological advancement has emerged as the new trend gaining popularity in the hot food processing equipment market. Major companies operating in the hot food processing equipment market are focused on developing new technological solutions such as automated processing, remote maintenance, and others to strengthen their position in the market. For instance, in May 2021, GEA Group, a Germany-based food systems and component company, launched the GEA OptiSlicer 6000, which incorporates a number of technological advancements to slice meat and cheese products more quickly, resulting in increased output and easier maintenance while maintaining ultimate precision. The higher blade capacity and online remote access allow real-time advice and intervention to verify parameters and error messages to rectify faults or optimize machine parameter settings, reducing downtime and maximizing productivity. In February 2022, Marel, an Iceland-based food processing solutions company, acquired Curio for an undisclosed amount. Through this acquisition, Marel's strategic goal is to be the one-stop shop for food processors looking for high-tech solutions, software, and services. Curio is a UK-based whitefish primary processing equipment company, specialising in cutting-edge heading, filleting, and skinning systems. Asia-Pacific was the largest region in the hot food processing equipment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hot food processing equipment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hot food processing equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hot food processing market includes revenues earned by entities by providing washing, chopping, pasteurizing, freezing, fermenting services .The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hot food processing equipment market research report is one of a series of new reports from The Business Research Company that provides hot food processing equipment market statistics, including global market size, regional shares, competitors with a hot food processing equipment market share, detailed hot food processing equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hot food processing equipment industry. This hot food processing equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users The global drugs for immunotherapy market size grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drugs for immunotherapy is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The drugs for immunotherapy market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. The high cost of drugs for the immunotherapy market is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth. Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of drugs for immunotherapy market are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. North America was the largest region in the immunotherapy market in 2022. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hot-melt-based adhesives are thermoplastic adhesives that are heated to create a melt before applying to the surface and are designed to be melted in an electric hot glue gun. The hot-melt-based adhesives are marketed in a solid state at room temperature, and these are activated through heating beyond their softening point between 50 and 160 degrees. The main types of hot-melt-based adhesives are thermoplastic polyurethane, ethylene vinyl acetate, styrenic-butadiene copolymers, polyolefins, polyamide, and other resin types. Polyamide is a polymer in which the amide group (CONH) connects the monomer units. The hot-melt-based adhesives are applied in packaging solutions, nonwoven hygiene products, furniture and woodwork, bookbinding, and other sectors that are used by building and construction, packaging, transportation, electrical and electronic appliances, healthcare, and other industries. The global hot-melt-based adhesives market is segmented - 1) By Type: Thermoplastic Polyurethane, Ethylene Vinyl Acetate, Styrenic-butadiene Copolymers, Polyolefins, Polyamide, Other Resin Types 2) By Application: Packaging Solutions, Nonwoven Hygiene Products, Furniture & Woodwork, Bookbinding, Other Applications 3) By End User: Building and Construction, Packaging, Transportation, Electrical and Electronic Appliances, Healthcare, Other End Users The global hot-melt-based adhesives market size will grow from $15.65 billion in 2022 to $17.04 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global hot-melt-based adhesives is expected to grow from $23.54 billion in 2027 at CAGR of 8.4%. With growing awareness to preserve the environment, customers/consumers are fetching for eco-friendly products. Features like affordability, non-release of VOC into the environment, longer shelf life, reusability without degradation, and fast-drying ability are making hot melt adhesives as environmentally friendly adhesives when compared to other adhesives. For example, companies such as Bostik are providing hot-melt polyurethane adhesive for the textile industry by using a solventless technology that reduces the usage of hazardous solvents like methylene chloride. Hot-melt polyurethane adhesive has seen visible success in Asian underwear, sportswear, and medical garment manufacturers. The increasing demand for hot-melt polyurethane adhesives will drive the hot melt adhesives market. Major players in the hot-melt-based adhesives market are Jowat Se, Sika AG, Tex Year Industries Inc., DowDuPont, Costchem SRL, American Chemical Inc., Bostik Inc., Huntsman Corp., Beardow & Adams Ltd., and Hexcel Corporation. Many products produced by adhesives companies are potentially hazardous during the manufacturing stages. This is mainly because the manufacturing processes involve high temperatures and high-pressure reactions, which can be dangerous unless controlled carefully. In addition, some of these manufactured dyes harm both living organisms and the environment. Due to this, regulations in the adhesives industry—in assessing and managing the risks involved in the manufacturing, transporting, and disposing of chemicals—increased in the historical period. Adhesives have to be compliant with complex regulations that govern the labeling, handling, manufacturing, shipping, and storage of the product. Additional compliance costs for these changing regulations, as different countries and geographies have different regulations, were a major restraint for hot melt-based adhesives companies. Many hot melt-based adhesive companies are adopting IoT (Internet of Things) technologies to connect equipment and smart devices to garner real-time insights and locate gaps in the manufacturing process. The data obtained is processed, analyzed, and interpreted by plant managers and senior-level management to improve quality and achieve optimum production levels. For example, smart systems give information on the working condition and performance of chemical reactors with embedded software and analytics tools to notify plant operators and managers of possible machine breakdowns. For instance, some of the major companies adopting IoT include BASF SE, The Dow Chemical Company, and H.B. Fuller. Asia-Pacific was the largest region in the hot-melt-based adhesives market in 2022. North America was the second-largest region in the global hot-melt-based adhesives market share. The regions covered in the global hot-melt-based adhesives market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hot melt-based adhesives market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The hot-melt-based adhesives market consists of the sales of hot-melt pressure-sensitive adhesives, and poly amides hot-melt adhesives. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hot-melt-based adhesives market research report is one of a series of new reports from The Business Research Company that provides hot-melt-based adhesives market statistics, including hot-melt-based adhesives industry global market size, regional shares, competitors with a hot-melt-based adhesives market share, detailed hot-melt-based adhesives market segments, hot-melt-based adhesives market trends and opportunities, and any further data you may need to thrive in the hot-melt-based adhesives industry. This hot-melt-based adhesives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gynecology drugs refer to a field of medicine that focuses on the treatment of illnesses of the female reproductive system, including care for women during pregnancy and childbirth. These drugs are used to treat gynecological diseases which include conditions and affecting the uterus, ovaries, and their appendages. The main types of therapeutics in gynecology drugs are hormonal therapy and non-hormonal therapy. Hormonal therapy is a treatment that adds, blocks or removes hormones to slow or stop the growth of cancer cells that need hormones to grow. Non-hormonal therapy involves the usage of anti-infective, anti-inflammatory agents, lubricants, moistures, antidepressants, gabapentin, clonidine and others. Gynecology drugs are used for gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception and others and distributed through hospital pharmacies, retail pharmacies and online pharmacies. The global gynecology drugs market is segmented - 1) By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy 2) By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Other Indications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global gynecology drugs market size will grow from $26.46 billion in 2022 to $28.09 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the gynecology drugs is expected to grow to $36.23 billion in 2027 at a CAGR of 6.6%. The rise in the number of women suffering from ovarian cancer would drive the growth of the global gynecological drugs market. For instance, according to Globocan, it is estimated that the global incidence of ovarian cancer will increase from 295,414 in 2018 to 434,184 by 2040. The increasing incidence of ovarian cancer would boost the market for gynecological drugs in the forecast period. Major players in the gynecology drugs market are Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Allergan, AstraZeneca, Bayer AG, AbbVie, TherapeuticsMD Inc., Lupin Pharmaceuticals Inc., Ferring Holding SA, Johnson & Johnson, GlaxoSmithKline PLC., Eli Lilly and Company, Amgen Inc., and Sanofi. Alternative treatment methods and natural remedies are increasingly becoming popular globally which is expected to have a negative impact on the revenues of gynecological drug companies. Treatments in the fields of homoeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for gynecological cancer. Many herbs used in Ayurveda have anti-cancer properties, for example, Curcumin, Holy Basil is said to inhibit the growth of cancerous cells and Ayurvedic gynecological procedures like Agnikarma help treat cervical erosion. This growing adoption of alternative treatments is expected to have a negative impact on the growth of the gynecology drugs market. Drug manufacturers are investing in developing personalized cancer vaccines, including gynecological cancers, and few have reached clinical trial phases. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments that are designed to treat specific patients. Moderna announced the result of the ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumours. The results were positive when mRNA mRNA personalized cancer vaccine (PCV) mRNA-4157, was given alone or in combination with Merck pembrolizumab (KEYTRUDA®). Currently, the vaccine is in phase 2 clinical trial. In January 2020, India-based capital market company True North announced the acquisition of India-based Glenmark Pharmaceuticals Ltd gynecology business in India and Nepal for $16.2 million (INR 115 crore). Through this acquisition, True North aims to further grow the gynecology portfolio of Glenmark and expanding presence in multiple geographies. North America was the largest region in the gynecology drugs market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the gynecology drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The gynecology drugs market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The gynecology drugs market research report is one of a series of new reports from The Business Research Company that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erectile dysfunction (ED) drugs refer to the drugs that are used to improve the effects of nitric oxide, a substance your body naturally generates that relaxes penile muscles, to treat erectile dysfunction. Erectile dysfunction is the inability to achieve or keep up a penile erection in men. The different types of drugs in erectile dysfunction (ED) drugs are sildenafil citrate, mirodenafil, and vardenafil. Sildenafil is a drug that is used to treat erectile dysfunction and pulmonary arterial hypertension. It is offered under the trade names Viagra and others. It’s unknown whether it’s effective in treating female genital dysfunction. The different routes of administration include Oral, topical, and injections and are used by hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for erectile dysfunction market is segmented - 1) By Drugs: Sildenafil Citrate, Mirodenafil, Vardenafil 2) By End users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Mode of Administration: Oral, Topical, Injections The global drugs for erectile dysfunction market size will grow from $3.21 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 1.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for erectile dysfunction market size is expected to grow to $3.36 billion in 2027 at a CAGR of 0.8%. The drastic increase in the number of chronic diseases drives the erectile dysfunction drug market. Erectile dysfunction is mainly caused by chronic diseases resulting from a sedentary lifestyle such as cardiovascular diseases, diabetes, obesity, and high blood pressure. According to WHO, the prevalence of chronic diseases is expected to grow by 57% by the end of the year 2020. Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drug market. Major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd., Vivus, Meda Pharmaceuticals, Apricus Biosciences, Cristália, S.K. Chemicals Co and Teva Pharmaceutical Industries Ltd. Patients suffering from erectile dysfunction do not seek treatment owing to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status. These factors are responsible for the patients suffering from erectile dysfunction rejecting or avoiding the treatment. For example, according to a survey conducted by Opinium Research in February 2020, just 27% out of the total 2,006 men surveyed were aware that erectile dysfunction could be linked to high blood pressure or elevated cholesterol while just 22% of men surveyed were aware that erectile dysfunction is often associated with diabetes. These factors restrain the growth of the erectile dysfunction drug market. New drug delivery techniques such as the use of pellets and creams are being implemented by many companies in the erectile dysfunction drugs market. Pellets and creams will have more efficacy and performance in erectile dysfunction and these are also more effective and safer to use. These benefits from drug delivery techniques will increase the scope of the erectile dysfunction drug market. For example, In September 2022, Lupin, an India-based pharmaceutical company launched Sildenafil for oral suspension, 10 mg/mL with the approval of the United States Food and Drug Administration (FDA). This drug is for erectile dysfunction with unique dosages. Medicines are authorized by regulatory bodies based on quality, safety, and efficacy to make sure that medicines are of standard quality and gives positive benefit. Companies are mandated to submit the documentation for the standard quality before applying for authorization. The safety and efficacy of medicines should be demonstrated by clinical trials for all new medicines by the companies. Competent authorities will assess this data before authorizing the drugs. In Europe, the European Medicines Agency (EMA) assesses the drugs for centrally authorized products. North America was the largest region in the erectile dysfunction (ED) drugs market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the global erectile dysfunction (ED) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the erectile dysfunction (ED) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The erectile dysfunction (ED) drugs market research report is one of a series of new reports from The Business Research Company that provides erectile dysfunction (ED) drugs market statistics, including erectile dysfunction (ED) drugs industry global market size, regional shares, competitors with erectile dysfunction (ED) drugs market share, detailed erectile dysfunction (ED) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction (ED) drugs industry. This erectile dysfunction (ED) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition that describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low-level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones, and others. The main types of drugs for hormonal replacement therapy are estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, and testosterone replacement therapy. The various routes of administration are oral, parental, and others which are distributed in hospital pharmacies, retail pharmacies, and online pharmacies. The therapies are applied for hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, and others. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Other Applications 4) By Route of Administration: Oral, Parental, Other Route of Administration The global drugs for hormonal replacement therapy market size will grow from $12.01 billion in 2022 to $12.66 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for hormonal replacement therapy is expected to grow to $14.63 billion in 2027 at a CAGR of 3.7%. The increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market . Hormonal replacement therapy drugs such as estrogen, progesterone, and others are used to treat medical conditions caused by menopausal conditions. For instance, in February 2021, according to the United Nations Economic and Social Commission for Asia and the Pacific, a Thailand-based regional commission, over half of the people who are over 65 are women, making up over 9% of the total population. By 2050, this percentage is projected to nearly double to more than 18%. From 1.7% to 4.9% of the population, the proportion of people over 80 will almost treble, with women making up over 60% of this group. There are a number of factors that could make older women more vulnerable than older men, including: According to the European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed the male population by 2060, out of which 59.6% of the female population is expected to suffer from postmenopausal symptoms. Thus, the growing female population suffering from menopausal symptoms and the aging population drive the growth of drugs for hormonal replacement therapy market Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co., Hisamitsu Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan PLC., QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech, and TherapeuticsMD. Increasing the occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder the growth of drugs for hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones), and other effects when women undergo hormone replacement therapy. A high dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer, and others. According to an online study, a decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinder the growth of drugs for hormonal replacement therapy. Companies in the drugs for hormonal replacement therapy industry are increasingly developing of drugs for hormonal replacement therapy market with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, virginal estrogen, and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others that occur due to low estrogen levels. Varginalestrogen in the form of cream, vaginal ring, and vaginal tablets is used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low-dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brand’s offerings of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-EstradiolDerm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System, and others. Department Of Health and Human Services of the Food and Drug Administration (FDA), a federal agency, is a regulatory body that monitors, controls, and regulates the drugs for hormone replacement therapy market. For instance, the FDA's Department Of Health and Human Services has revised the requirements for specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by the FDA is to establish the effectiveness and ensure safety for any over-the-counter drug use of these ingredients. North America was the largest region in the drugs for hormonal replacement therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for hormonal replacement therapy market share during the forecast period. The regions covered in the global drugs for hormonal replacement therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The drugs for hormonal replacement therapy market includes revenues earned by entities by treating common menopausal symptoms, including hot flashes and vaginal discomfort. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The drugs for hormonal replacement therapy market research report is one of a series of new reports from The Business Research Company that provides drugs for hormonal replacement therapy market statistics, including drugs for hormonal replacement therapy industry global market size, regional shares, competitors with drugs for hormonal replacement therapy market share, detailed drugs for hormonal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for hormonal replacement therapy industry. This drugs for hormonal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Women’s health devices refer to devices that enable them to take control of their health and health-related data with at-home tests and other features. The women’s health devices are used to enhance women's healthcare, including maternal and menstrual health, pelvic and sexual health, fertility, menopause, and contraception, as well as many general health disorders that affect women disproportionately or differently, such as osteoporosis or cardiovascular disease. The main product types of women’s health devices are surgical, diagnostics, contraceptives, labor and delivery, and critical care. A surgical device refers to a specialized device used by surgeon to relieve a medical condition. The applications of women’s health devices include cancer, osteoporosis, infectious disease, uterine fibroids, post-menopausal syndrome, pregnancy, female sterilization, and other applications. The various end-users of women’s health devices include hospitals, obstetrics and gynecology clinics, diagnostic laboratories, ambulatory surgical centers, and other end users. The global women’s health devices market is segmented - 1) By Product: Surgical, Diagnostics, Contraceptives, Labor and Delivery, Critical Care 2) By Type: Devices, Consumables 3) By Application: Cancer, Osteoporosis, Infectious Disease, Uterine Fibroids, Post-menopausal Syndrome, Pregnancy, Female Sterilization, Other Applications 4) By End-user: Hospitals, Obstetrics and Gynaecology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centres, Other End Users The global women’s health devices market size grew from $33.89 billion in 2022 to $36.95 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global women’s health devices is expected to grow to $52.54 billion in 2027 at a CAGR of 9.2%. An increase in government programs aimed at raising awareness about women’s health is contributing to the growth of the women’s health devices market going forward. Government programs aimed at raising awareness about women’s health refer to initiatives and awareness events organized by the government to make the population aware of some societal boosting the public healthcare system's efficiency and effectiveness. These government programs help in creating awareness, which in turn increases the need for women's health devices for easy diagnosis. For instance, in March 2022, according to the Department of Health, Victoria, the Victorian government released its first-ever women’s sexual and reproductive health strategy and priority action plan for women’s sexual and reproductive health. The plan is supported by a $6.6 million investment for action and education to reduce stigma and improve knowledge of sexual and reproductive health and other such issues. Therefore, an increase in government programs aimed at raising awareness about women’s health is expected to boost demand for women’s health devices during the forecast period. Major players in the women’s health devices market are Abbott Laboratories, Koninklijke Philips N.V., CooperSurgical, F. Hoffmann-La Roche, Caldera Medical, GE Healthcare, Carestream Health, Hologic, Medline Industries, Candence Inc., Boston Scientific Corporation, Reckitt Benckiser, BD. Com, Coloplast A/S, and MedGyn Products, Inc. Technological advancement is a key trend gaining popularity in the women’s health devices market. Many companies operating in the women’s health devices sector are looking for new technologies to strengthen their position in the women’s health devices market. For instance, in May 2022, iSono Health, a US-based medical equipment manufacturing company, launched ATUSA, which is the world’s first portable and automated 3D breast ultrasound scanner. This combines a unique 3D ultrasound scanner with artificial intelligence to perform full breast scans and accurately locate breast tumors. It automatically captures the entire breast volume, allowing for unremarkable breast ultrasound imaging at the point of care without the need for a trained ultrasound driver. This launch represents another step forward for the company and the female population. In February 2022, CooperSurgical, a US-based women’s healthcare brand, acquired Cook Medical's reproductive health portfolio for an amount of $875 million. With this acquisition, both companies aim to invest in future growth and new technologies. Cook Medical is a US-based company that manufacturers invasive medical devices for fertility, obstetrics, gynaecology, in vitro fertilization, and assisted reproductive technology. North America was the largest region in the women’s health devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the women’s health devices market report during the forecast period. The regions covered in the women’s health devices industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the women’s health devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The women’s health devices market consists of sales of contraceptive devices and pharmaceuticals, densitometry, breast implants, obstetrics/gynecology biopsy and imaging. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The women’s health devices market research report is one of a series of new reports from The Business Research Company that provides women’s health devices market statistics, including women’s health devices industry global market size, regional shares, competitors with a women’s health devices market share, detailed women’s health devices market segments, market trends and opportunities, and any further data you may need to thrive in the women’s health devices industry. This women’s health devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.